ICER assessed GSK's COPD treatments, Trelegy Ellipta and Breo Ellipta, for clinical effectiveness and value. The report will aid CMS in negotiating drug prices. Both inhalers offer advantages with once-daily dosing. Patient feedback and observational data support their efficacy.